Preparation method of human nerve growth factor transgenic pig

A growth factor, human nerve technology, applied in nerve growth factor, growth factor/inducing factor, biochemical equipment and methods, etc., can solve the problems of low protein production efficiency, difficult separation, unfavorable hNGF purification and extraction, etc. The effect of avoiding immunogenicity problems

Inactive Publication Date: 2020-08-07
SOUTH CHINA AGRI UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Various methods have been used to obtain hNGF, such as in vitro cultured animal cells, transgenic Escherichia coli and yeast, etc., but due to low production efficiency or the inability to obtain correct post-translational modifications of the protein, these methods have not been implemented in production. application level
Another study used a transgenic animal mammary gland bioreactor to prepare hNGF, which improved the production of hNGF, but there are still defects: mammary gland bioreactor is subject to animal sex (female) and physiological cycle (postpartum lactation period); Contains a large number of protein types and quantities, which is not conducive to the subsequent purification and extraction of hNGF
However, since the endogenous NGF gene of pigs has not been knocked out, pig NGF (pig NGF, pNGF) is still contained in pig saliva, and the physical and chemical properties of pNGF and hNGF are similar, so it is difficult to separate the two

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of human nerve growth factor transgenic pig
  • Preparation method of human nerve growth factor transgenic pig
  • Preparation method of human nerve growth factor transgenic pig

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] The gene sequence of SEQ ID NO: 2 involved in the present invention is derived from GenBank accession number: NM_002506.2; the gene sequence of SEQ ID NO: 3 is derived from GenBank accession number: NM_002506.2; the gene sequence of SEQ ID NO: 4 is derived from GenBank accession number: X01697.1.

[0024] 1. Construction of CRISPR / Cas9 system expression vector targeting pNGF gene exons

[0025] Select the CRISPR / Cas9 system expression vector plasmid pX330-U6-Chimeric-BB-CBh-hSpCas9 (hereinafter referred to as pX330 plasmid), and connect the linearized pX330 plasmid vector with the annealed sgRNA 5 and sgRNA RT3 respectively to construct sgRNA 5 and sgRNA RT3-guided CRISPR / Cas9 system expression vector targeting pNGF gene exons (attached figure 1 ).

[0026]

[0027]

[0028] 2. Construction of a homologous recombination vector providing hNGF gene

[0029] The 54bp long signal peptide sequence (SEQ ID NO:3) in the 726bp long hNGF gene original sequence (SEQ ID N...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a preparation method of a human nerve growth factor transgenic pig. The method comprises the following steps: a, constructing a CRISPR / Cas9 system expression vector of a targeted pNGF gene exon, b, constructing a homologous recombinant vector for providing an hNGF gene, c, co-transfecting porcine ear fibroblasts with the CRISPR / Cas9 system expression vector and the homologous recombinant vector of the hNGF gene, and d, screening the transfected porcine ear fibroblasts to obtain a positive cell line, and cloning somatic cells to obtain the transgenic pig with the human nerve growth factor. According to the invention, by a fixed-point gene recombination mode, the hNGF gene is insert into a pig pNGF gene locus, therefore, the obtained transgenic pig with the human nerve growth factor can express the human nerve growth factor without expressing the pig nerve growth factor, so that the current situation that when the human NGF is collected in pig saliva, the human NGF is mixed in the pig saliva is avoided, the problem of immunogenicity when the pig is used for drug therapy is also avoided, and the transgenic pig is safer and more effective.

Description

technical field [0001] The invention relates to an animal obtained by a transgenic method and a preparation method thereof, in particular to a preparation method of a transgenic pig transformed with human nerve growth factor. Background technique [0002] Nerve growth factor (NGF) is a neurotrophic protein that maintains the survival of neurons, promotes their growth and differentiation, and plays an important role in the development of animals and various physiological processes of adult animals. In addition, NGF plays an important auxiliary role in the growth and activity maintenance of non-nerve cells such as immune cells, fibroblasts, pancreatic cells, and cardiomyocytes, as well as in the repair of tissue damage. Therefore, NGF has good clinical or potential therapeutic effects on many neurological and non-neurological diseases and injuries. [0003] NGF drugs currently on the market are mainly extracted from the submandibular gland of mice, that is, mouse NGF (mouse N...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/90C12N15/877C12N15/85A01K67/027C07K14/48
CPCA01K67/0278A01K2217/072A01K2227/108A01K2267/01C07K14/48C12N15/8509C12N15/8778C12N15/907C12N2800/107
Inventor 吴珍芳李紫聪邝哲曾芳廖莎朱庆春蔡更元郑恩琴杨化强杨杰洪林君顾婷徐铮黄思秀
Owner SOUTH CHINA AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products